KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Non-cash Items (2016 - 2025)

Fulgent Genetics (FLGT) has disclosed Non-cash Items for 11 consecutive years, with $852000.0 as the latest value for Q4 2025.

  • Quarterly Non-cash Items rose 535.82% to $852000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $852000.0 through Dec 2025, up 535.82% year-over-year, with the annual reading at $852000.0 for FY2025, 535.82% up from the prior year.
  • Non-cash Items hit $852000.0 in Q4 2025 for Fulgent Genetics, up from $134000.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $21.0 million in Q4 2021 to a low of $134000.0 in Q4 2024.
  • Historically, Non-cash Items has averaged $6.5 million across 5 years, with a median of $4.9 million in 2023.
  • Biggest five-year swings in Non-cash Items: plummeted 97.27% in 2024 and later surged 535.82% in 2025.
  • Year by year, Non-cash Items stood at $21.0 million in 2021, then crashed by 74.15% to $5.4 million in 2022, then fell by 9.48% to $4.9 million in 2023, then tumbled by 97.27% to $134000.0 in 2024, then soared by 535.82% to $852000.0 in 2025.
  • Business Quant data shows Non-cash Items for FLGT at $852000.0 in Q4 2025, $134000.0 in Q4 2024, and $4.9 million in Q4 2023.